Local Immunosuppression of Organ Transplants

Section A: Background.- 1. Local Regulation of Allograft Rejection.- 2. Pharmacokinetic Advantage of Regional Drug Delivery.- 3. Early Studies of Local Immunosuppression (1964–1984).- Section B: Pump-Based Local Infusion in Rat Allograft Models.- 4. Selective Immunosuppression by Local Treatment of the Allograft: Studies on Intrarenal Prednisolone and Intracardiac Budesonide Delivery in the Rat.- 5. Local Immunosuppression of Rat Cardiac, Liver, and Small Bowel Allografts.- 6. Inhibition of Cardiac Allograft Rejection by Continuous Local Infusion of 16,16 Di-Methyl PGE2.- 7. Intrarenal Administration of Anti T Cell-Monoclonal Antibody.- 8. Intraportal Delivery of Immunosuppressants to Intrahepatic Islet Allografts.- Section C: Pump-Based Local Infusion in Canine Allograft Models.- 9. Local Heparin, 6-Mercaptopurine, Prednisolone, and Mizoribine Delivery in a Canine Renal Allograft Model.- 10. Intraportal Cyclosporine A in Canine Liver Transplantation.- Section D: Other Drug Targeting Systems for Achieving Local Immunosuppression.- 11. Liposomal Cyclosporine A.- 12. Liposomal FK506 in a Canine Hepatic Allograft Model.- 13. Cyclosporine Aerosol in Lung Transplantation.- 14. Site-Specific Immunosuppression with Topical Agents.- 15. Local Immunosuppression in Corneal Transplantation.- 16. Controlled-Release Drug Matrices for Local Immunosuppression of Organ Transplants.- 17. Gene Transfer to the Transplanted Organ.- 18. Immunomodulation of Islet Allografts with Genetically Modified Muscle Cells.- 19. Sertoli Cells in Islet Transplantation: Testicular Immune Privilege.- Section E: Conclusion.